As previously reported, Leerink analyst Mike Kratky upgraded Tandem Diabetes to Outperform from Market Perform with a price target of $45, up from $34, alongside the firm’s MEDACorp U.S. Diabetes Survey. Since its October 2023 initiation, Leerink has warmed up to Tandem for a number of reasons. Alongside its latest MEDACorp U.S. Diabetes Survey, the firm feels that it now has enough evidence to support its new positive investment recommendation on the stock. Overall, Leerink sees an attractive risk/reward setup for Tandem on both a near-term and longer-term basis at the current valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $40 from $37 at Stifel
- Tandem Diabetes price target raised to $38 from $31 at Citi
- Reddit initiated, Seagate upgraded: Wall Street’s top analyst calls
- Tandem Diabetes upgraded to Buy at Stifel on strong Mobi adoption
- Tandem Diabetes upgraded to Buy from Hold at Stifel
